Abstract
Background
Medullary thyroid carcinoma (MTC) is an infrequent form malignant tumor with a poor prognosis. Because of the influence of competitive risk, there may suffer from bias in the analysis of prognostic factors of MTC.
Methods
By extracting the data of patients diagnosed with MTC registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1998 to 2016, we established the Cox proportional-hazards and competing-risks model to retrospectively analyze the impact of related factors on lymph nodes statistically.
Results
A total of 2,435 patients were included in the analysis, of which 198 died of MTC. The results of the multifactor competing-risk model showed that the number of total lymph nodes (19–89), positive lymph nodes (1–10,11–75) and positive lymph node ratio (25%-53%,>54%), age (46–60,>61), chemotherapy, mode of radiotherapy (others), tumor size(2-4cm,>4cm), number of lesions greater than 1 were poor prognostic factors for MTC. For the number of total lymph nodes, unlike the multivariate Cox proportional-hazards model results, we found that it became an independent risk factor after excluding competitive risk factors. Competitive risk factors have little effect on the number of positive lymph nodes. For the proportion of positive lymph nodes, we found that after excluding competitive risk factors, the Cox proportional-hazards model overestimates its impact on prognosis. The competitive risk model is often more accurate in analyzing the effects of prognostic factors.
Conclusions
After excluding the competitive risk, the number of lymph nodes, the number of positive and the positive proportion are the poor prognostic factors of medullary thyroid cancer, which can help clinicians more accurately evaluate the prognosis of patients with medullary thyroid cancer and provide a reference for treatment decision-making.
Publisher
Public Library of Science (PLoS)
Reference35 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;H Sung;CA: a cancer journal for clinicians,2021
2. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma;SA Wells;Thyroid: official journal of the American Thyroid Association,2015
3. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems;E Kebebew;Cancer,2000
4. Medullary thyroid carcinoma: a narrative historical review;A Wong;Expert review of anticancer therapy
5. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years;RW Randle;Surgery,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献